• Home
  • Commercial & Medical
  • UniQure’s Huntington’s gene therapy is delayed, as FDA suggests it may walk back accelerated approval blessing

UniQure’s Huntington’s gene therapy is delayed, as FDA suggests it may walk back accelerated approval blessing

UniQure’s stock was in freefall Monday morning after the company announced that it might not be able to submit its Huntington’s disease gene therapy for FDA approval on the originally planned timeline.

UniQure

Subscribe for Updates

Copyright 2025 dijee Intelligence Ltd.   dijee Intelligence Ltd. is a private limited company registered in England and Wales at Media House, Sopers Road, Cuffley, Hertfordshire, EN6 4RY, UK registeration number 16808844